Normal tissue antigen (NTA)

Normal tissue antigen is not a specific identifiable molecule or receptor but a generic term referring to antigens expressed on healthy, non-cancerous cells. It is often discussed in the context of immunotherapy challenges like CAR T-cell toxicity. "Normal tissue antigen" (often abbreviated NTA) lacks a defined canonical name, gene symbol, or protein sequence, as it describes any antigen found on normal cells rather than a singular entity. In immunotherapy literature, particularly CAR T-cell research, it contrasts with tumor-associated antigens (TAAs); therapies targeting shared TAAs can cause on-target, off-tumor toxicity by attacking normal tissues expressing low levels of the antigen. Examples include antigens like TROP2 (expressed in lung, skin, kidney), HLA alleles, or epithelial markers used in inhibitory CAR (iCAR) designs to prevent such damage via AND-NOT logic gates, where an activating CAR targets tumor antigens while an iCAR inhibits upon NTA binding. No specific drugs directly target "normal tissue antigen" as a therapeutic entity, and it is not classified as a receptor, enzyme, or other druggable protein class. This vagueness renders it unsuitable as a precise therapeutic target, with discussions focusing on mitigation strategies rather than direct modulation. Reliable sources like PubMed and peer-reviewed journals (e.g., PNAS, Frontiers in Immunology) confirm its use as a conceptual category without molecular specificity.

Other names

NTA